Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R) (PrE0506)(PSCI#20-123)
Participants may receive the medication Durvalumab in addition to standard of care medications or standard of care medications alone for treatment of Mesothelioma.
unable to surgically remove pleural mesothelioma post menopausal or negative pregnancy test greater than 66 pounds in weight life expectancy of at least 12 weeks
Exclusion Criteria:
prior chemotherapy autoimmune disease metastasized to the brain